Losing participants before the trial ends erodes credibility of findings

Jun Xia; Clive Adams; Nishant Bhagat; Vinaya Bhagat; Paranthaman Bhoopathi; Hany El-Sayeh; Vanessa Pinfold; Yahya Takriti

doi:10.1192/pb.bp.108.021949

Losing participants before the trial ends erodes credibility of findings

Jun Xia, Clive Adams, Nishant Bhagat, Vinaya Bhagat, Paranthaman Bhoopathi, Hany El-Sayeh, Vanessa Pinfold, Yahya Takriti

Nottingham China Health Institute

Research output: Journal Publication › Article › peer-review

126 Citations (Scopus)

Abstract

AIMS AND METHOD: To estimate the proportion of attrition at which results of drug trials for people with schizophrenia lose enough credibility to become mistrusted by relevant groups of stakeholders. A piloted questionnaire was sent to 128 local clinicians, 100 relevant researchers and 104 service users and carers. RESULTS: We received the biggest number of responses from the service user and carer group (n=81, 76%); 43% of clinicians and 32% of researchers responded. All three groups suggested that the follow-up rate for a 12-week schizophrenia drug trial should be around 70-75% for the trial to be credible. CLINICAL IMPLICATIONS: This survey suggests that relevant stakeholders, including researchers, fundamentally mistrust results of the majority of drug trials in schizophrenia. Adopting a more pragmatic trial design can help address this.

Original language	English
Pages (from-to)	254-257
Number of pages	4
Journal	Psychiatric Bulletin
Volume	33
Issue number	7
DOIs	https://doi.org/10.1192/pb.bp.108.021949
Publication status	Published - Jul 2009

ASJC Scopus subject areas

Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1192/pb.bp.108.021949

Cite this

@article{314c1986688b4782a2d921d252dec132,

title = "Losing participants before the trial ends erodes credibility of findings",

abstract = "AIMS AND METHOD: To estimate the proportion of attrition at which results of drug trials for people with schizophrenia lose enough credibility to become mistrusted by relevant groups of stakeholders. A piloted questionnaire was sent to 128 local clinicians, 100 relevant researchers and 104 service users and carers. RESULTS: We received the biggest number of responses from the service user and carer group (n=81, 76%); 43% of clinicians and 32% of researchers responded. All three groups suggested that the follow-up rate for a 12-week schizophrenia drug trial should be around 70-75% for the trial to be credible. CLINICAL IMPLICATIONS: This survey suggests that relevant stakeholders, including researchers, fundamentally mistrust results of the majority of drug trials in schizophrenia. Adopting a more pragmatic trial design can help address this.",

author = "Jun Xia and Clive Adams and Nishant Bhagat and Vinaya Bhagat and Paranthaman Bhoopathi and Hany El-Sayeh and Vanessa Pinfold and Yahya Takriti",

year = "2009",

month = jul,

doi = "10.1192/pb.bp.108.021949",

language = "English",

volume = "33",

pages = "254--257",

journal = "BJPsych Bulletin",

issn = "2056-4694",

publisher = "Royal College of Psychiatrists",

number = "7",

}

TY - JOUR

T1 - Losing participants before the trial ends erodes credibility of findings

AU - Xia, Jun

AU - Adams, Clive

AU - Bhagat, Nishant

AU - Bhagat, Vinaya

AU - Bhoopathi, Paranthaman

AU - El-Sayeh, Hany

AU - Pinfold, Vanessa

AU - Takriti, Yahya

PY - 2009/7

Y1 - 2009/7

N2 - AIMS AND METHOD: To estimate the proportion of attrition at which results of drug trials for people with schizophrenia lose enough credibility to become mistrusted by relevant groups of stakeholders. A piloted questionnaire was sent to 128 local clinicians, 100 relevant researchers and 104 service users and carers. RESULTS: We received the biggest number of responses from the service user and carer group (n=81, 76%); 43% of clinicians and 32% of researchers responded. All three groups suggested that the follow-up rate for a 12-week schizophrenia drug trial should be around 70-75% for the trial to be credible. CLINICAL IMPLICATIONS: This survey suggests that relevant stakeholders, including researchers, fundamentally mistrust results of the majority of drug trials in schizophrenia. Adopting a more pragmatic trial design can help address this.

AB - AIMS AND METHOD: To estimate the proportion of attrition at which results of drug trials for people with schizophrenia lose enough credibility to become mistrusted by relevant groups of stakeholders. A piloted questionnaire was sent to 128 local clinicians, 100 relevant researchers and 104 service users and carers. RESULTS: We received the biggest number of responses from the service user and carer group (n=81, 76%); 43% of clinicians and 32% of researchers responded. All three groups suggested that the follow-up rate for a 12-week schizophrenia drug trial should be around 70-75% for the trial to be credible. CLINICAL IMPLICATIONS: This survey suggests that relevant stakeholders, including researchers, fundamentally mistrust results of the majority of drug trials in schizophrenia. Adopting a more pragmatic trial design can help address this.

UR - http://www.scopus.com/inward/record.url?scp=67650789837&partnerID=8YFLogxK

U2 - 10.1192/pb.bp.108.021949

DO - 10.1192/pb.bp.108.021949

M3 - Article

AN - SCOPUS:67650789837

SN - 2056-4694

VL - 33

SP - 254

EP - 257

JO - BJPsych Bulletin

JF - BJPsych Bulletin

IS - 7

ER -

Losing participants before the trial ends erodes credibility of findings

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this